Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Cardiomyopathy, Renal Impairment

In brief

To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and renal (kidney) dysfunction.

Key facts

Study ID

NCT01970176

Run by

Mayo Clinic

People needed

20

Starts

2014-01-09

Expected to finish

2019-09-01

Last updated by the study team

2021-06-11

Who can join

Age: 21 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A total of 39 patients with PSD as defined by an ejection fraction of less than 40%, no clinical signs or symptoms of congestive heart failure, a minimal distance on 6-minute walk of equal or >450 meters will be recruited and calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the (MDRD-measurement of renal dysfunction, formula) assessed within the past 24 months. If the subject is not able to walk 450 meters due to pain in hips and knees and not fatigue or shortness of breath than they will still qualify for the protocol.

You may not qualify if…

• Current or anticipated future need for nitrate therapy
• Systolic blood pressure < 90 mmHg or > 180 mm Hg
• Diastolic blood pressure < 40 mmHg or > 100 mmHg
• Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum proteases inhibitors for HIV) who cannot be taken off these medications for the duration of the study.
• Patients taking the following selective alpha blockers and who are unable to stop for the duration of the study;
• Alfuzosin
• Prazosin
• Doxazosin
• Tamsulosin
• Terazosin
• Silodosin
• Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy or unexplained visual disturbance
• Patients with sickle cell anemia, multiple myeloma, leukemia or penile deformities placing them at risk for priapism (angulation, cavernosal fibrosis or Peyronie's disease)
• Patients with an allergy to iodine.
• Patients on PDEV inhibition for pulmonary hypertension
• Patients on PDEV inhibition for erectile dysfunction who are not willing to stop the medication for the duration of the study
• Valve disease (> moderate aortic or mitral stenosis; > moderate aortic or mitral regurgitation)
• Obstructive Hypertrophic cardiomyopathy
• Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)
• Pericardial disease
• Have experienced a myocardial infarction or unstable angina, or have undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent
• Severe congenital heart diseases
• Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening
• Second or third degree heart block without a permanent cardiac pacemaker
• Stroke within 3 months of screening or other evidence of significantly compromised Central Nervous System (CNS) perfusion

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.